Targeting the Pathophysiology of Diabetic Macular Edema by Romero-Aroca, Pedro
Targeting the Pathophysiology of Diabetic
Macular Edema
D
iabeticmacularedema(DME)isthe
leadingcauseofblindnessinthedi-
abetic population, and its preva-
lence is variable. The Diabetes Control
and Complications Trial (DCCT) re-
ported that 27% of type 1 diabetic pa-
tients developed macular edema within 9
years of diabetes onset (1). Other studies
indicate that in type 2 diabetic patients
the prevalence increases from 3% within
5 years of diagnosis to 28% after 20 years
duration (2). DME tends to be a chronic
disease,althoughspontaneousrecoveryis
not uncommon. It is important to recog-
nize that 33–35% of patients with mac-
ular edema had spontaneous resolution
after 6 months if untreated. To character-
ize the severity of macular edema and for
treatment guidelines, the term clinically
signiﬁcant macular edema (CSME) as an
equivalent of DME, deﬁned by the Early
Treatment of Diabetic Retinopathy Study
(ETDRS), is used.
DMEisacomplexdiseaseofmultifac-
torial origin. The common pathway that
results in DME is disruption of the blood-
retinal barrier (BRB). The mechanism of
BRB breakdown is multifactorial and sec-
ondary to changes in the tight junctions,
pericyte loss, endothelial cell loss, retinal
vessel leukostasis, upregulation of vesic-
ular transport, and increased permeabil-
ity of the surface membranes of retinal
vessels and retinal pigment epithelium
cells. The disruption of the BRB leads to
abnormal inﬂow of ﬂuid into the neuro-
sensoryretinathatcanexceedtheoutﬂow
and cause residual accumulation of ﬂuid
in the intraretinal layers of the macula.
The pathogenesis includes the exis-
tence of chronic hyperglycemia, along
with the accumulation of free radicals,
AGE proteins, and protein kinase C
(PKC) formation, and the subsequent ac-
tivation of vascular endothelial growth
factors (especially VEGF-A) as well as an
increase in vascular permeability. Like-
wise, the appearance of areas of ischemia
and inﬂammatory factors, such as inter-
leukin 6, also increase the synthesis of
VEGF-A.Allofthesefactorsmaybeinter-
related. For example, hypoxia and hyper-
glycemia upregulate VEGF-A production
in diabetic retinopathy, which in turn in-
creases vasopermeability by activating
PKC. Hyperglycemia, however, can di-
rectly increase PKC and angiotensin II,
both of which cause vasoconstriction and
worsening of hypoxia by their effect on
endothelins (3).
To treat DME, it is important to use
theclassiﬁcationbyBresnicketal.(4)into
focal or diffuse DME. This classiﬁcation
depends on the leakage pattern seen on
the ﬂuorescein angiogram (FA). In focal
CSME, discrete points of retinal hyper-
ﬂuorescence are present on the FA due to
focal leakage of microaneurysms. In dif-
fuse macular edema, areas of diffuse leak-
agearenotedontheFAduetointraretinal
leakage from a dilated retinal capillary
bed and/or intraretinal microvascular ab-
normalities, and/or, in severe cases, from
arterioles and venules, without discrete
foci of leaking microaneurysms. The rel-
evance of this classiﬁcation is due to the
different treatment that we can use. For
focal macular edema, the laser treatment
is responsive. However, in the diffuse
form of macular edema, the effectiveness
ofphotocoagulationhasnotbeendemon-
strated; for this disease, a grid laser pho-
tocoagulation technique developed many
years ago may reduce leakage attributable
to permeability abnormalities within di-
lated macular capillaries with a positive
effect on visual acuity and ﬂuorescein
leakage, but its use has been dropped of
late due to its poor results in ﬁnal visual
acuity (5).
Because of the poor results obtained
with laser photocoagualtion in diffuse
DME, alternatives to treatment based on
its pathogenesis have been sought. The
Diabetic Retinopathy Clinical Research
Network (6) reported 2-year results of a
multicenter randomized clinical trial
comparing preservative-free intravitreal
triamcinolone (at two concentrations: 1
mg and 4 mg) with focal/grid laser for
DME. The mean visual acuity after start-
ing the treatment was better in the laser
group, although seemed to improve more
rapidly in the 4-mg triamcinolone group.
This study demonstrated that intravitreal
injection of triamcinolone acetonide is a
promisingtherapyforDMEunresponsive
to laser photocoagulation. However, the
triamcinolone is an off-label treatment,
and its use is not without complications.
Surgical cataracts succeeded in 51%, and
an increase of intraocular pressure ap-
peared in 30% of the patients. Other ste-
roids, such as Retisert (ﬂuocinolone
acetonide) and Porsudex (dexametha-
sone), are currently undergoing phase III
trials.
As discussed at the beginning,
VEGF-A is a major mediator of increased
retinal permeability. Blockage of VEGF-A
has been shown to reduce vascular per-
meability.Currently,wehaveachievedits
inhibition via VEGF-A inhibitors with
aptamers (pegaptanib) or antibodies tar-
geted against VEGF-A (e.g., ranibizumab
or bevacizumab). The preliminary results
of the clinical trial of VEGF-A (VEGF-165
isoform) with pegaptanib has demon-
strated a beneﬁcial effect of this intravit-
real drug on visual acuity and retinal
thickness in a phase II trial (7), and phase
III trials are underway.
Ranibizumab and bevacizumab are
antibodies targeted against VEGF-A that
have been widely used to treat exudative
age-relatedmaculardegeneration.Bevaci-
zumab is an off-label drug, and its use is
under study. Ranibizumab is an anti-
VEGF Fab fragment commonly used in
the treatment of age-related macular de-
generation. There are currently ﬁve mul-
ticenter, randomized phase II/III trials
that aim to determine the safety and efﬁ-
cacyofthisdruginthetreatmentofDME.
Massin et al. (8) demonstrated in a
12-month phase II study that the mean
visual acuity improved from baseline by
10.3  9.1 letters with ranibizumab and
declined by 1.4  14.2 with sham (P 
0.0001). Additionally, the proportion of
patientswhogained10lettersaswellas
15 letters was threefold higher in the
ranibizumab arm than in the sham arm.
The mean change in central retinal thick-
nesswassigniﬁcantlyhigherintheranibi-
zumab arm with a decrease of 194.2 vs.
48.4 m in the sham arm. There were no
imbalances in the rates of ocular and no-
nocular adverse events between the two
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events were conjunctival hemorrhage
(22.5%), intraocular increase (20.6%),
and eye pain (17.6%). A special feature of
this study is the possibility of dose dou-
bling, which was eventually undertaken
inthemajorityofranibizumabpatients.A
total of 86% of patients received a dose of
0.5mgorhigherduringmostofthestudy
period, and the investigators in fact rec-
ommended a dose of 0.5 mg to replicate
the efﬁcacy.
This study appears promising for the
useoftheranibizumabinthetreatmentof
DME, with a good safety proﬁle. Anti-
VEGF drugs seem to be a promising alter-
native for the treatment of DME, but it is
still necessary to deﬁne the dose and the
time between injections. However, we
must determine if they can be used as a
monotherapy or in combination with
other treatments, such as laser photoco-
agulation. A clinical trial directly compar-
ing the efﬁcacy and safety of anti-VEGF
treatmentwithconventionallasertherapy
is warranted.
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